FDA: Gene-Editing Sponsors Can Reuse Platform Data Across Programs
The FDA's June 2 draft guidance lets gene therapy developers leverage prior CMC, nonclinical and clinical data across programs incorporating genome editing. The shift lands as Beam Therapeutics...
business20channel.tv